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Summary
Background: The angiographic no-reﬂow phenomenon after primary percutaneous
coronary intervention (PCI) carries a poor prognosis in patients with ST-segment
elevation myocardial infarction (STEMI). However, the type of plaque composition
that associates with the angiographic no-reﬂow phenomenon remains unclear.
Methods: A total of 44 patients with STEMI were enrolled in this study. After
thrombectomy with an aspiration catheter, virtual histology intravascular ultrasound
(VH-IVUS) of the infarct-related vessel was performed. Patients were divided into
two groups according to ﬁnal thrombolysis in myocardial infarction (TIMI) ﬂow grade
at the completion of PCI procedure. Complete reperfusion group (CR-group) was
deﬁned as ﬁnal TIMI ﬂow grade 3, and no-reﬂow group (NR-group) was deﬁned as
ﬁnal TIMI ﬂow 2. The relationship between plaque composition and angiographic
no-reﬂow phenomenon was analyzed.
Results: The angiographic no-reﬂow phenomenon was observed in 20 individuals.
The summation of the percentage of ﬁbrofatty + necrotic core and ﬁbrofatty + dense
calcium was signiﬁcantly higher in the NR-group. Receiver-operating characteristics
analysis revealed that the summation of the volume and percentage of ﬁbro-
fatty + necrotic core (>20.1mm3, 26.2%) and ﬁbrofatty + dense calcium (>20.0mm3,
22.6%) predict the angiographic no-ﬂow phenomenon.
∗ Corresponding author. Tel.: +81 895 25 1111; fax: +81 895 25 5334.
E-mail address: okousei@yahoo.co.jp (K. Ohshima).
914-5087/$ — see front matter © 2009 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
oi:10.1016/j.jjcc.2009.05.009
206 K. Ohshima et al.
Conclusion: The ﬁbrofatty-rich component with necrotic core or dense calcium
derived from VH-IVUS is closely related to the angiographic no-reﬂow phenomenon
observed in primary PCI.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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IVUS imaging and analysis
The VH-IVUS data were recorded onto the imaging© 2009 Japanese Colleg
reserved.
Introduction
Primary percutaneous coronary intervention (PCI)
is recognized as an effective treatment for ST-
segment elevation acute myocardial infarction
(STEMI) [1,2]. However, 10—20% of cases with pri-
mary PCI are associated with distal embolization
resulting in the no-reﬂow phenomenon, which is
characterized by impaired myocardial perfusion
despite achievement of full patency of epicardial
coronary artery [3,4], and associated with poor
prognosis [5,6].
Various mechanisms are responsible for the
development of the no-reﬂow phenomenon [7].
Several studies by gray-scale intravascular ultra-
sound (IVUS) have shown that pre-interventional
IVUS ﬁndings such as lipid-pool-like image and
positive remodeling are associated with the angio-
graphic no-reﬂow phenomenon during primary PCI
[8—11].
Recently, virtual histology intravascular ultra-
sound (VH-IVUS) (Volcano Therapeutics, Inc.,
Rancho Cordova, CA, USA), which characterizes
plaque composition as four different phenotypes
(ﬁbrous, ﬁbrofatty, necrotic core, and dense cal-
cium) has become clinically available to assess both
plaque morphology and its composition. Nasu and
colleagues demonstrated that in vivo characteriza-
tion of plaques by VH-IVUS correlates well with in
vitro histological tissue samples obtained by direc-
tional coronary atherectomy [12]. However, the
type of plaque composition that associates with
no-reﬂow in patients with STEMI remains to be elu-
cidated. The purpose of this study was to assess
the relationship between plaque composition and
no-reﬂow phenomenon observed in primary PCI by
VH-IVUS.
Methods
Study populationIn this single-center study, 44 consecutive patients
with de novo STEMI were enrolled from January
2007 to December 2007. The inclusion criteria were
as follows: (1) presentation within 6 h of symp
s
p
u
com onset; (2) chest pain lasting more than 30min
nd resistant to nitrates; (3) more than 0.2mV ST-
egment elevation in at least 2 continuous leads on
2-lead electrocardiography (ECG); (4) an infarct-
elated coronary artery with a reference lumen
iameter more than 2.5mm by visual estimation
hat was deemed suitable for stent placement; and
5) by angiography, coronary artery occlusion or
ub-occlusion (thrombolysis in myocardial infarc-
ion [TIMI] ﬂow grade less than 2 on diagnostic
ngiography). Left main trunk artery lesions were
xcluded.
rimary PCI procedure and deﬁnition of
o-reﬂow phenomenon
ll patients were premedicated with aspirin
200mg orally) and clopidogrel (300mg orally),
nd unfractionated heparin (10,000 IU) was admin-
stered intravenously just before the procedure.
mmediately after the angiography, the culprit
esion was crossed with a conventional guidewire.
hen, an aspiration catheter was advanced over
he guidewire, and the lesion was fully aspirated.
20-MHz, 3.2-F phased-array IVUS catheter (Eagle
ye, Volcano Therapeutics Inc.) was placed distal
o the lesion, and it was pulled back at 1.0mm/s
o the proximal part of the lesion with an auto-
otorized pullback system. Stent deployment was
erformed immediately after IVUS analysis. At the
ompletion of the PCI procedures, TIMI ﬂow grade
13], corrected TIMI frame counts (CTFC) [14],
IMI myocardial perfusion (TMP) grade [15], and
T-segment resolution (STR) [16] were evaluated.
atients were divided into two groups according to
yocardial perfusion state after primary PCI. Com-
lete reperfusion group (CR-group) was deﬁned as
nal TIMI ﬂow grade 3. No-reﬂow group (NR-group)
as deﬁned as ﬁnal TIMI ﬂow 2.ystem hard disk, and analyses were independently
erformed by experienced analysts who were
naware of the angiographic ﬁndings and baseline
linical and lesion characteristics. All measure-
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Velationship between plaque composition and no-re
ents were automatically derived from Volcano
5 imaging system software (Volcano Therapeu-
ics Inc.). Lumen and media areas were measured.
laque area was calculated as the difference
etween media area and lumen area [17]. The
H-IVUS data analysis was based on gray-scale
order contour calculation, and the tissue maps
ere provided by the software [green = ﬁbrous (F);
ellow=ﬁbrofatty (FF); red = necrotic core (NC);
nd white = dense calcium (DC)]. Volumes were
utomatically determined by the software, and
he summation of measured cross-sectional areas
n all frames of the pullback region was based
n Simpson’s rule. The individual percentages of
laque components in the total plaque volume
ere calculated. Remodeling index was calcu-
ated as lesion divided by the proximal reference
xternal elastic membrane cross-sectional area.
ositive remodeling was deﬁned as a remodeling
ndex >1.0, and intermediate/negative remodel-
ng was deﬁned as a remodeling index 1.0 [18].
requency of plaque with ultrasonic attenuation
nd lipid-pool-like image were evaluated accord-
ng to the previously described methods [8,19,20].
VUS-derived thin-cap ﬁbroatheroma (ID-TCFA) was
eﬁned as a necrotic core more than 10% of plaque
rea at either the minimal luminal area site or the
argest necrotic core site in more than 3 consecu-
ive frames without evident overlying ﬁbrous tissue
n the presence of more than 40% plaque burden
21]. Spotty calciﬁcation was deﬁned as a lesion
hat contained only small calcium deposits within
n arc of less than 90◦ [22]. Frequency of ID-TCFA
nd spotty calciﬁcation at stent site (per 10mm)
ere also evaluated.
tatistical analysis
uantitative variables are presented as mean± SD
nd categorical variables as percentages. Contin-
ous variables were compared with the Student’s
-test and categorical data with the Fisher’s
xact or chi-square tests. Correlation between
otal plaque volume and each plaque composition
as evaluated by using linear regression models.
eceiver-operating characteristic (ROC) analysis
as used to determine the optimal cut-off value
or each plaque component volume for the pre-
iction of the angiographic no-reﬂow phenomenon
fter primary PCI. The cut-off point was deﬁned as
he greatest sum of the sensitivity and speciﬁcity
stimates. The area under the ROC curve (AUC)
as used as a measure of test accuracy. All statis-
ical analyses were performed with SPSS software
SPSS, Inc., Chicago, IL, USA). All p values <0.05
ere considered statistically signiﬁcant.
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esults
aseline clinical and procedural
haracteristics
aseline clinical and procedural characteristics are
isted in Table 1. There were no signiﬁcant differ-
nces in coronary risk factors between two groups.
here were no signiﬁcant differences in onset to
dmission time and reperfusion time. The stent size
as similar in both groups. On the other hand,
he stent length was signiﬁcantly longer in the
R-group than the CR-group (46.3± 27.5mm vs.
5.7± 10.9mm, p = 0.002). There was no signiﬁ-
ant difference in peak creatine kinase between
oth groups. The CTFC was signiﬁcantly prolonged
n the NR-group than the CR-group (49.6± 18.6 vs.
6.9± 5.1, p < 0.0001). The frequency of STR >50%
as lower in the NR-group than the CR-group (25%
s. 100%, p < 0.0001).
he differences of plaque morphology by
ray-scale IVUS between CR-group and
R-group
able 2 lists morphological ﬁndings of the cul-
rit lesion in the CR-group and the NR-group by
ray-scale IVUS. There were no signiﬁcant dif-
erences in plaque volume between both groups.
he degree of positive remodeling was signiﬁ-
antly greater in the NR-group than in the CR-group
1.26± 0.17 vs. 1.12± 0.19, p = 0.01). The fre-
uency of plaque rupture, lipid-pool-like image,
nd ultrasonic attenuation were signiﬁcantly higher
n the NR-group than in the CR-group (95% vs. 63%,
= 0.01; 50% vs. 0%, p < 0.0001; and 75% vs. 0%,
< 0.0001, respectively). The frequency of the ID-
CFA at stent site was signiﬁcantly higher in the
R-group (85% vs. 54%, p = 0.029). The average
umber of ID-TCFA per 10mm at the stent site was
igniﬁcantly greater in the NR-group than the CR-
roup (0.78± 0.51 vs. 0.34± 0.38, p = 0.003). The
requency of spotty calciﬁcation was signiﬁcantly
igher in the NR-group (100% vs. 79%, p = 0.03).
he average number of spotty calciﬁcation at cul-
rit site was signiﬁcantly greater in the NR-group
1.33± 0.70 vs. 0.56± 0.50, p < 0.0001).
he differences in plaque composition by
H-IVUS between CR-group and NR-groupable 3 lists plaque composition of the culprit lesion
omparing the CR-group and the NR-group by VH-
VUS. As shown in the table, the percentage of F
as signiﬁcantly greater in the CR-group than the
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Table 1 Baseline clinical and procedural characteristics.
CR-group (n = 24) NR-group (n = 20) P-value
Age (year) 66.0± 14.0 74.0± 14.0 0.079
Male 20 (83%) 13 (65%) 0.17
Hypertension 14 (58%) 15 (75%) 0.26
Hypercholesterolemia 15 (63%) 9 (45%) 0.26
Diabetes mellitus 13 (54%) 12 (60%) 0.71
Current smoker 16 (67%) 8 (40%) 0.08
Onset to admission time (min) 131± 36 133 ± 56 0.87
Reperfusion time (min) 175± 37 168 ± 64 0.65
Infarct-related artery 0.24
Left anterior descending 10 12
Right 10 6
Left circumﬂex 4 2
Initial TIMI 0 10 (42%) 13 (65%) 0.17
Rentrop grade 2/3 5 (21%) 5 (25%) 0.75
Maximal stent size (mm) 3.4± 0.4 3.6± 0.5 0.27
Total stent length (mm) 25.7± 10.9 46.3± 27.5 0.002
Peak creatine kinase (IU/l) 2141 ± 2015.7 3275.7± 2743.7 0.14
Corrected TIMI frame counts 16.9± 5.1 49.6± 18.6 <0.0001
myo
a
t
i
n
R
p
pST-segment resolution > 50% 19 (96%)
CR, complete reperfusion; NR, no reﬂow; TIMI, thrombolysis in
NR-group (67.8± 10.2% vs. 57.5± 10.7%, p = 0.002).
In contrast, both the volume and the percentage of
FF were signiﬁcantly higher in the NR-group than
the CR-group (14.2± 11.4mm3 vs. 8.6± 5.2mm3,
p = 0.036, and 14.5± 9.6% vs. 10.1± 3.9%, p = 0.04,
respectively). There were no signiﬁcant differences
in NC and DC between both groups.
Volumetric VH-IVUS analysis of FF +NC and
FF +DC were signiﬁcantly greater in the NR-
group than in the CR-group (28.3± 12.3mm3 vs.
20.5± 9.3mm3, p = 0.025, and 24.5± 11.1mm3 vs.
15.0± 7.2mm3, p = 0.002, respectively). In addi-
tion, the percentage of FF +NC and FF +DC were
signiﬁcantly greater in the NR-group than the
CR-group (30.3± 7.0% vs. 24.3± 6.1%, p = 0.005,
W
n
p
i
o
Table 2 Differences in plaque morphology by gray-scale in
(CR) group and no-reﬂow (NR) group.
CR-group (n = 2
Plaque volume (mm3) 83.6± 28.4
Plaque burden (%) 59.3± 7.4
Remodeling index (ratio) 1.12± 0.19
Positive remodeling 18 (75%)
Plaque rupture 15 (63%)
Lipid-pool-like image 0 (0%)
Ultrasonic attenuation 0 (0%)
ID-TCFA 13 (54%)
Number of ID-TCFA 0.34± 0.38
Spotty calciﬁcation 19 (79%)
Number of spotty calciﬁcations 0.56± 0.50
ID-TCFA, intravascular ultrasound derived thin-cap ﬁbroatheroma.5 (25%) <0.0001
cardial infarction.
nd 26.3± 8.5% vs. 17.9± 5.6%, p = 0.001, respec-
ively). Representative examples of VH-IVUS images
n patients with or without the no-reﬂow phe-
omenon are shown in Fig. 1.
OC analysis of the volume and the
ercentage of plaque composition for
rediction of no-reﬂow after primary PCIe performed ROC analysis to determine the diag-
ostic accuracy of each plaque composition for
redicting the no-reﬂow phenomenon. As shown
n Table 4, both the volume and the percentage
f FF +NC or FF +DC had larger AUC as com-
travascular ultrasound between complete reperfusion
4) NR-group (n = 20) P-value
95.1± 42.4 0.31
60.7± 6.9 0.53
1.26± 0.17 0.01
19 (95%) 0.07
19 (95%) 0.01
10 (50%) <0.0001
15 (75%) <0.0001
17 (85%) 0.029
0.78± 0.51 0.003
20 (100%) 0.03
1.33± 0.70 <0.0001
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Table 3 The differences in plaque composition by virtual histology intravascular ultrasound between complete
reperfusion (CR) group and no-reﬂow (NR) group.
CR-group (n = 24) NR-group (n = 20) P-value
Each plaque component
Absolute volumes (mm3)
Fibrous 56.6 ± 21.8 56.2 ± 32.6 0.96
Fibrofatty 8.6 ± 5.2 14.2 ± 11.4 0.036
Dense calcium 6.5 ± 5.3 10.3 ± 7.6 0.063
Necrotic core 12.0 ± 7.4 14.1 ± 6.7 0.32
Percentages
Fibrous 67.8 ± 10.2 57.5 ± 10.7 0.002
Fibrofatty 10.1 ± 3.9 14.5 ± 9.6 0.04
Dense calcium 7.8 ± 5.2 11.8 ± 8.9 0.08
Necrotic core 14.3 ± 6.7 15.8 ± 7.4 0.49
Summation of two plaque components
Absolute volumes (mm3)
Necrotic core and dense calcium 18.4 ± 12.2 24.5 ± 12.5 0.12
Fibrofatty and necrotic core 20.5 ± 9.3 28.3 ± 12.3 0.025
Fibrofatty and dense calcium 15.0 ± 7.2 24.5 ± 11.1 0.002
Percentages
Necrotic core and dense calcium 22.1 ± 11.0 27.5 ± 14.6 0.17
Fibrofatty and necrotic core 24.3 ± 6.1 30.3 ± 7.0 0.005
Fibrofatty and dense calcium 17.9 ± 5.6 26.3 ± 8.5 0.001
Figure 1 Representative examples of virtual histology intravascular ultrasound images in patients with or without the
no-reﬂow phenomenon. F, ﬁbrous; FF, ﬁbrofatty; NC, necrotic core; DC, dense calcium.
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Table 4 Receiver-operating characteristics analysis of the volume and the percentages of the plaque component
and no-reﬂow phenomenon.
AUC Cut-off value Sensitivity (%) Speciﬁcity (%) 95%CI
Each plaque component
Volumes (mm3)
Fibrous 0.435 44 50 33.3 0.259—0.612
Fibrofatty 0.638 7.6 60 50 0.471—0.804
Necrotic core 0.592 9.8 75 54.2 0.418—0.765
Dense calcium 0.667 6.7 70 79.2 0.496—0.837
Percentages (%)
Fibrous 0.249 60.5 50 25 0.102—0.396
Fibrofatty 0.623 9.6 65 55.8 0.454—0.791
Necrotic core 0.556 11.1 70 37.5 0.381—0.732
Dense calcium 0.601 6.9 60 58.3 0.426—0.776
Summation of two plaque components
Volumes (mm3)
Necrotic core and dense calcium 0.631 16.1 75 58.3 0.456—0.806
Fibrofatty and necrotic core 0.705 20.1 65 58.3 0.549—0.855
Fibrofatty and dense calcium 0.771 22 75 70.8 0.596—0.891
Percentages (%)
Necrotic core and dense calcium 0.606 18.4 70 45.8 0.432—0.781
Fibrofatty and necrotic core 0.744 26.2 75 62.5 0.596—0.891
(
(Fibrofatty and dense calcium 0.79 22.6
pared with other VH-IVUS parameters. The AUC of
the volume of FF +NC and FF +DC was 0.705 and
0.771, and the AUC of the percentage of FF +NC
and FF +DC was 0.744 and 0.790, respectively.
The optimal cut-off point (sensitivity/speciﬁcity) to
predict the no-reﬂow phenomenon was 20.1mm3
t
2
a
F
Figure 2 Receiver-operating characteristics (ROC) curves for
demonstrated the good diagnostic value of FF +NC and FF +DC
ST-segment elevation myocardial infarction. AUC, area unde
necrotic core; DC, dense calcium.70 79.2 0.651—0.928
65.0%/58.3%) for the volume of FF +NC and 26.2%
75.0%/62.5%) for the percentage of FF +NC. On
he other hand, the optimal cut-off point was
2.0mm3 (75.0%/70.8%) for the volume of FF +DC
nd 22.6% (70.0%/79.2%) for the percentage of
F +DC (Fig. 2).
the prediction of the no-reﬂow phenomenon. ROC curves
in predicting the no-reﬂow phenomenon in patients with
r the curve; CI, conﬁdence interval; FF, ﬁbrofatty; NC,
R ﬂow
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ielationship between plaque composition and no-re
iscussion
y using VH-IVUS, we demonstrated that angio-
raphic no-reﬂow phenomenon is closely related
ith not only plaque morphological character
ut also plaque composition at culprit lesions in
atients with STEMI following primary PCI. The
ajor ﬁndings of this study were as follows. (1)
mong the VH-IVUS-derived components, the cul-
rit plaque of those with the no-reﬂow phenomenon
ontained signiﬁcantly larger amount of ﬁbro-
atty component than in those without no-reﬂow
henomenon. (2) ROC analysis revealed that the
olume and the percentage of FF +NC (>20.1mm3,
6.2%) and FF +DC (>20.0mm3, 22.6%) predict no-
ow phenomenon after primary PCI.
With regard to the plaque morphology detected
y gray-scale IVUS in patients with acute coro-
ary syndrome (ACS), recent clinical studies have
hown that pre-intervention ﬁndings including lipid-
ool-like images, positive remodeling, and ruptured
laque are predictable risk factors for the angio-
raphic no-reﬂow phenomenon [8—11,19—21]. In
he present study, gray-scale data were in line with
reviously published data, showing that the cul-
rit lesions of patients with no-reﬂow phenomenon
end to have larger remodeling index with higher
ncidence of plaque rupture, TCFA at stent site,
ltrasonic attenuation, and spotty calciﬁcation as
ompared to those without no-reﬂow phenomenon.
ur data conﬁrm that culprit lesions with these
ray-scale IVUS ﬁndings are prone to cause distal
mbolism following primary PCI. Furthermore, we
emonstrated that not only plaque morphology by
ray-scale IVUS but also plaque composition by VH-
VUS plays an important role in the development
f no-reﬂow phenomenon following primary PCI.
oth the volume and the percentage of ﬁbrofatty
omponent in the culprit plaques were signiﬁcantly
reater in patients with no-reﬂow phenomenon,
ndicating the importance of ﬁbrofatty-rich plaque
etection by VH-IVUS prior to mechanical dilata-
ion.
Several mechanisms have been postulated for
he no-reﬂow phenomenon observed during pri-
ary PCI [7]. Recent reports with distal protection
evices revealed that not only thrombus but also
iberated plaque debris released from mechan-
cally disrupted vulnerable plaque during stent
eployment contribute to the ﬂow complication
bserved in primary angioplasty. Tanaka and col-
eagues demonstrated that lipid-pool-like image
etected by gray-scale IVUS is an independent pre-
ictor for the no-reﬂow phenomenon in reperfused
MI [8]. In addition, a recent study using VH-IVUS
y Kawaguchi et al. demonstrated that the necrotic
ﬁ
c
f
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ore volume predicts the ST-segment re-elevation
fter stent implantation in primary angioplasty
23]. These data indicate that lipid core detected
s ‘‘lipid pool’’ or ‘‘necrotic core’’ by IVUS is one
f the important predictors for distal embolization
uring PCI. On the other hand, various factors other
han necrotic core are known to be responsible for
istal embolization during primary PCI. Porto and
olleagues demonstrated that changes in plaque
olume correlate well with myocardial necrotic
olume measured by magnetic resonance imaging
fter PCI [24]. In the present study, both volume and
ercentage of ﬁbrofatty component were closely
ssociated with no-reﬂow phenomenon, suggesting
he importance of plaque burden and its quality for
he development of distal embolization in primary
CI.
One of the salient features of ACS plaque is
haracterized by its histopathological heterogene-
ty. The vulnerable plaque contains fragile tissues
uch as lipid deposition with foam cells, intramu-
al thrombus, and ﬁbrofatty-rich component [25].
hus, they are thought to be easily liberated as
mbolic particles during stent implantation [26].
n addition to the importance of necrotic core in
he development of the no-reﬂow phenomenon,
hara et al. have reported that spotty calciﬁca-
ion was frequently observed in culprit plaques
n patients with acute myocardial infarction [22].
n our study, the incidence of spotty calciﬁcation
as more frequent in patients with no-reﬂow phe-
omenon, suggesting that dense calcium also plays
n important role in the development of no-reﬂow
henomenon.
The physical property as well as chemical com-
onent also affects culprit plaques in ACS. Schaar et
l. demonstrated that the strain value of fatty tis-
ue was signiﬁcantly higher than ﬁbrous tissue by
ntravascular palpography, suggesting that plaque
omposition may have inﬂuence on the plaque phys-
cal stiffness [27]. In our study, the volume and
ercentage of ﬁbrofatty component was closely
ssociated with the development of no-reﬂow
henomenon. A large amount of ﬁbrofatty-rich
omponent in culprit plaques is thought to result
n the plaque fragility with subsequent massive
ebris liberation during mechanical dilatation.
aken together, ﬁbrofatty component in the pres-
nce of necrotic core and spotty calciﬁcation may
ontribute to the distal embolization encountered
n primary PCI, indicating that the summation of
brofatty component and necrotic core or dense
alcium possibly predict the no-reﬂow phenomenon
ollowing primary PCI.
In situ thrombus formation plays a crucial role
n the development of acute luminal occlusion of
f
w
n
u
2
d
P
a
p
R212
culprit lesions in patients with STEMI. However, the
current classiﬁcation tree of VH-IVUS cannot differ-
entiate the presence of thrombus located in the ACS
plaque, and there are potential limitations for eval-
uation of ACS plaque by VH-IVUS. To date, there was
no study that investigated the direct comparison
between VH-IVUS ﬁndings and histopatholoy in cul-
prit lesions of STEMI, and phenotypic manifestation
of thrombus by VH-IVUS is still poorly understood.
Nasu and colleagues have shown that thrombus is
colored as ﬁbrous and ﬁbrofatty by VH-IVUS [12].
In our study, in spite of sufﬁcient thrombectomy
through aspiration catheter, the presence of resid-
ual thrombus in the culprit lesions may affect our
results for plaque composition analysis by VH-IVUS.
Further evaluation with histopathology or other
diagnostic modalities such as angioscopy or opti-
cal coherence tomography is required to conﬁrm
our results. In addition, the incidence of no-reﬂow
phenomenon was relatively higher in our study as
compared with previous reports [3,4], possibly due
to the small number of study participants. So, fur-
ther investigation with more patient numbers is
required to diminish unfavorable bias.
It is well known that no-reﬂow phenomenon fol-
lowing distal embolization is associated with poor
functional and clinical outcomes [5,6]. Therefore,
prevention of the no-reﬂow phenomenon with the
aim of myocardial protection is an essential goal for
primary PCI. Although distal protection devices may
prevent the no-reﬂow phenomenon during primary
angioplasty, their efﬁcacy remains controversial
[28,29]. Routine use of distal protection devices in
STEMI cannot be recommended, they are expected
to be effective in decreasing myocardial damage
in selected patients with high risk of no-reﬂow
phenomenon. In the present study, we revealed
that the major predictors of no-reﬂow phenomenon
were the volume and the percentage of FF +NC
and FF +DC determined by VH-IVUS. Taken together,
our data suggest that distal protection devices are
expected to be effective in carefully selected cul-
prit plaques with the volume and the percentage of
FF +NC (>20.1mm3, 26.2%) and FF +DC (>20.0mm3,
22.6%). Further clinical study is required to inves-
tigate the impact of distal protection in high-risk
patients with these VH-IVUS ﬁndings on the thera-
peutic efﬁcacy and prognosis.Conclusions
In addition to plaque morphological character
derived from gray-scale IVUS, the ﬁbrofatty com-
ponent with necrotic core or dense calcium derived
[K. Ohshima et al.
rom VH-IVUS at the culprit lesion in patients
ith STEMI is closely related to the angiographic
o-reﬂow phenomenon during primary PCI. The vol-
me and the percentage of FF +NC (>20.1mm3,
6.2%) and FF +DC (>20.0mm3, 22.6%) could pre-
ict no-ﬂow phenomenon observed in primary
CI. Pre-interventional VH-IVUS may provide useful
dditional information for the prediction of no-ﬂow
henomenon in primary PCI in patients with STEMI.
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